

INDEX

A

- Abdominal desmoid tumors (see Desmoid, tumors, abdominal)
ABO blood group compatibility: in heart transplant, *Sept.*, 621-622
Achalasia: and esophageal carcinoma, *July*, 484
Acyclovir: in posttransplant lymphoproliferative disorder, *June*, 415
Adenocarcinoma
esophagus, incidence and etiology of, *July*, 485-487
pancreatoduodenectomy for, results of, *May*, 359
- Age
as contraindication to heart transplant, *Sept.*, 618-619
desmoid tumor distribution by, *Apr.*, 264-267, 268-269
desmoid tumor growth rate and, *Apr.*, 271
desmoid tumor recurrence and, *Apr.*, 304
donor selection for heart transplant and, *Sept.*, 625
esophageal carcinoma surgery and mortality, *Aug.*, 544
at onset of esophageal carcinoma, *July*, 487
AIDS: lymphoid tumors in, *June*, 384-385
Allen test, *Feb.*, 81-82
false-positive result, *Feb.*, 83
normal result, *Feb.*, 83
Allogeneic response: recognized sites of immunosuppressant action in, *June*, 388
c-AMP: prostaglandins and transplantation, *Nov.*, 735-736
Angiography: of desmoid tumor in gluteal region, *Apr.*, 291
Anomalies in desmoid tumor patients
bone, inherited, *Apr.*, 281-285
- radiologic, *Apr.*, 277
localization of, *Apr.*, 279
Antibiotic prophylaxis: for overwhelming postsplenectomy infections, *Dec.*, 805-806
- Antibody
molecule, schematic of, *June*, 443
monoclonal, OKT3, in transplantation, *June*, 387, 389
Anticancer drugs: in desmoid tumors, *Apr.*, 300-301
- Antigen(s)
immunoglobulin response to, after splenectomy, *Dec.*, 775-777
presenting cells, and prostaglandins, *Nov.*, 736
stimulation, allograft, prostaglandin release by, *Nov.*, 733
- Anti-inflammatory drugs: nonsteroidal, in desmoid tumors, *Apr.*, 301
- Antilymphocyte globulin: Minnesota, in transplantation, *June*, 389
- Antithymocyte globulin: rabbit, in heart transplantation, *Sept.*, 650
- Arrhythmias: due to pulmonary artery catheterization, *Feb.*, 111-114
- Arteries
axillary (see Axillary artery)
blood sampling, complications of, *Feb.*, 92
brachial (see Brachial, artery)
brachiocephalic (see Brachiocephalic, artery)
carotid, in desmoid tumor patient, *Apr.*, 298
catheters, *Feb.*, 80
digital, occlusion due to radial artery catheterization, *Feb.*, 86, 87
femoral, catheterization, complications of, *Feb.*, 90-91

- Arteries (cont.)**
- gastric, left, nodal metastases from esophageal carcinoma along, Aug., 561
 - gastroduodenal, in pancreatico-duodenal resection, May, 343
 - hepatic (see Hepatic, arteries)
 - phlebotomy, complications of, Feb., 92
 - pressure monitoring, Feb., 77-92
 - site selection, Feb., 81-82
 - pulmonary (see Pulmonary, artery)
 - pulse-pressure wave tracings, Feb., 79
 - radial (see Radial artery)
 - small (see Vaso-occlusive disorders of upper extremity, small artery)
 - splenic, major branches of, Dec., 762
 - subclavian (see Subclavian, artery)
 - ulnar, thrombosis, digital vessels in, Jan., 27
 - vertebral, laceration due to attempted central venous catheterization, Feb., 96
- Arteriography**
- mesenteric
 - portal vein anatomy on, Mar., 164
 - in portal vein thrombosis, Mar., 207
 - in small artery occlusive disorders of upper extremity, Jan., 15-17
 - interpretation of, Jan., 16-17
 - technical considerations, Jan., 16
 - splenic
 - portal venous anatomy on, Mar., 165
 - in splenic injuries, Dec., 770-771
- Arteriosclerosis: accelerated graft, after heart transplant, Sept., 659-660**
- Arteritis**
- axillary artery in, Jan., 37-39
 - giant cell, axillary and subclavian arteries in, Jan., 39
- Arthritis: rheumatoid, digital vessels of upper extremity in, Jan., 23**
- Ascites, Mar., 214-217**
- evaluation of, Mar., 215
 - management of
 - medical, Mar., 215-216
 - surgical, Mar., 216
 - pathogenesis of, Mar., 215
- Atherosclerosis: digital vessels of upper extremity in, Jan., 20**
- Atrioventricular block: during pulmonary artery catheterization, Feb., 113**
- Axillary artery**
- catheterization, complications of, Feb., 91-92
 - occlusion, Jan., 37-42
 - in arteritis, Jan., 37-39
 - in arteritis, giant cell, Jan., 39
 - embolic, Jan., 40-41
 - irradiation injury causing, Jan., 39-40
 - operative approach, Jan., 41-42
 - trauma causing occlusion, Jan., 40
- Axillosubclavian vein repair: in Parson-Schroetter syndrome, transclavicular approach for, Jan., 58-59**
- Azathioprine: in heart transplantation, Sept., 649-650**

B

- Billingham criteria: for diagnosing rejection by endomyocardial biopsy, Sept., 652**
- Biochemical evaluation: of variceal bleeding, Mar., 161**
- Biologic role: of prostaglandins, Oct., 683**
- Biopsy**
- endomyocardial, in cardiac rejection, Sept., 651-654
 - liver, in variceal bleeding, Mar., 162-163

- Bleeding (see Variceal bleeding)
- Block: atrioventricular, during pulmonary artery catheterization, *Feb.*, 113
- Blood
- cellular changes after splenectomy, *Dec.*, 778
 - dyscrasias, digital vessels of upper extremity in, *Jan.*, 25
 - group compatibility in heart transplant, ABO, *Sept.*, 621–622
 - sampling, arterial, complications of, *Feb.*, 92
 - transfusion-induced immunosuppression, and prostaglandins, *Nov.*, 739
- Bone
- anomalies, inherited, and desmoid tumor, *Apr.*, 281–285
 - resorption, and prostaglandins, *Oct.*, 690–691
 - Bony metastases: and prostaglandins, *Oct.*, 693–694
 - Bougienage: in advanced carcinoma of esophagus and cardia, *Aug.*, 580–581
 - Bowel posttransplant lymphoproliferative disorder: after renal transplant, *June*, 421, 422
 - Brachial
 - artery
 - catheterization, complications of, *Feb.*, 92
 - occlusion, *Jan.*, 42–44
 - pressure assessment, Doppler flow detector for, *Jan.*, 12
 - thrombus (see Thrombus, brachial artery)
 - plexus, desmoid tumor around, strategy for removal of, *Apr.*, 295 - Brachiocephalic
 - artery occlusion, *Jan.*, 29–44
 - anatomical considerations, *Jan.*, 29–30
 - pressure measurements in, *Jan.*, 14
- vessels, reconstructive techniques using, *Jan.*, 32
- Brain death
- criteria for, *Sept.*, 625
 - heart transplant and, *Sept.*, 625, 628–629
- Breast masses: female, 16-keto-PGF_{1α} and thromboxane in, *Oct.*, 695
- Brunschwig's pancreatoduodenectomy, *May*, 332
- Budd-Chiari syndrome, *Mar.*, 209–214
- evaluation of, *Mar.*, 210–211
 - management of, *Mar.*, 212–214
 - pathology of, *Mar.*, 210
 - shunt for, mesoatrial, *Mar.*, 213
- Buerger's disease: digital vessels of upper extremity in, *Jan.*, 25
- Bullae: due to radial artery catheterization, *Feb.*, 89
- Burkitt's lymphoma, *June*, 380–381
- Bypass procedures: for advanced carcinoma of esophagus and cardia, *Aug.*, 582–585

C

- Cachexia: as contraindication to heart transplant, *Sept.*, 620
- Calcium channel blockers: for vasospastic disorders of upper extremity, *Jan.*, 28
- Cancer
- (See also Carcinoma)
 - as contraindication to heart transplant, *Sept.*, 621
 - heart and neck, and esophageal carcinoma, *July*, 485
 - immune system and, historical considerations, *June*, 373–376
 - prostaglandins and, *Oct.*, 683–700
 - immune system and, *Oct.*, 689–690
- Carcinoma
- (See also Cancer)
 - adenocarcinoma (see Adenocarcinoma)

- Carcinoma, esophagus and cardia, *July*, 481-531; *Aug.*, 541-605
advanced
 bougienage for, *Aug.*, 580-581
 bypass procedures for, *Aug.*, 582-585
 intubation for, *Aug.*, 581-582,
 583
 laser therapy for, *Aug.*, 586-587
 palliative therapy for, *Aug.*,
 580-587
 radiotherapy for, *Aug.*, 585-586
algorithm of surgical oncology
 decisions in management of,
 July, 507
cervical
 esophagolaryngectomy for,
 completed, *Aug.*, 558
 radiotherapy for, survival after,
 Aug., 552
surgery for, *Aug.*, 551-558
surgery for, operative tech-
 nique, *Aug.*, 554-557
surgery for, results of, *Aug.*,
 557-558
surgery for, survival after, *Aug.*,
 552
swallowing ability after ther-
 apies for, *Aug.*, 553
chemotherapy for, combined
 with radiotherapy, *Aug.*,
 594-595
classification of primary tumor,
 July, 493-497
determining stage of disease, *July*,
 499-501
dysphagia in (see Dysphagia in
 esophageal carcinoma)
electrical coagulation therapy for,
 Aug., 587
esophagogastrectomy for (see
 Esophagogastrectomy for
 carcinoma of esophagus and
 cardia)
FEV₁ and, *Aug.*, 543
lymph node involvement in, clas-
 sification of, *July*, 497-499
metastases from, distant organ,
 classification of, *July*, 499
pathology of, *July*, 490-492
performance status classification,
 July, 502
perioperative supportive mea-
 sures, *Aug.*, 545-549
postsurgical resection classifica-
 tion, *July*, 500
preoperative evaluation, *Aug.*,
 542-549
presentation of, *July*, 487-489
 age at, *July*, 487
prognostic factors, incidence of
 tumor size and relationship
 of tumor size to, *July*, 505
radiotherapy for, combined with
 chemotherapy, *Aug.*, 594-595
radiotherapy for, postoperative,
 Aug., 592
radiotherapy for, preoperative,
 Aug., 587-591
"downstaging" and, *Aug.*, 590
effect on operative mortality,
 Aug., 590
effect on resectability, *Aug.*, 588
effect on treatment morbidity,
 Aug., 591
protocol, *Aug.*, 588
 results of studies, *Aug.*, 589
survival and, *Aug.*, 591
radiotherapy for, vs. surgery, *July*,
 508-510
resection for
 (See also Esophagogastrectomy
 combined with chemotherapy),
 Aug., 592-595
en bloc, curative, extent of,
 July, 514-519
en bloc, curative vs. palliative,
 July, 510-512
in smokers, *July*, 483
squamous cell, incidence and
 etiology of, *July*, 481-485
staging of, *July*, 492-504
surgery of
 classification and, *July*, 507-508
 current controversies, *July*,
 507-522
 effect of tumor location on
 choice of procedure, *Aug.*,
 549-551
 history of, *Aug.*, 541-542

- mortality of, and age, Aug., 544
- physiologic assessment and, Aug., 542-545
- vs. radiotherapy, July, 508-510
- therapy for, combination, Aug., 587-595
- thoracic
- clinical approach to, July, 504-507
 - en bloc resection for, Aug., 570-580
 - en bloc resection for, operative technique, Aug., 572-576
 - en bloc resection for, postoperative classification after, Aug., 578
 - en bloc resection for, reconstruction of GI tract with left colon interposition after, Aug., 575
 - en bloc resection for, results of, Aug., 576-580
 - staging for, intraoperative, July, 501-504
 - surgery for, Aug., 559-580
 - survival after various therapies for, Aug., 577
- Carcinosarcoma: Walker, effects of cyclooxygenase inhibition on, Oct., 693
- Cardia (see Carcinoma, esophagus and cardia)
- Cardiac (see Heart)
- Cardiectomy: view of recipient cuffs and great vessels after, Sept., 630
- Carotid artery: in desmoid tumor patient, Apr., 298
- Catheter(s)
- arterial, Feb., 80
 - jejunostomy feeding, method of securing, Aug., 549
 - pulmonary artery, Feb., 101-102
 - entanglement, Feb., 110-111
 - kinking, Feb., 108
 - knotting, Feb., 110-111
 - migration from time of insertion to 6 hours later, Feb., 106
- movement of distal portion from balloon deflated to balloon inflated, Feb., 105
- related infections, Feb., 126-129
- identification of, Feb., 125-126
- Catheterization
- axillary artery, complications of, Feb., 91-92
 - brachial artery, complications of, Feb., 92
 - cardiac, brachial artery thrombus after, Jan., 44
 - central venous, Feb., 92-97
 - complications of, Feb., 94-97
 - indications for, Feb., 93
 - femoral artery, complications of, Feb., 90-91
 - jugular vein, internal, complications of, Feb., 95-97
 - pulmonary artery, Feb., 97-124
 - arrhythmias due to, Feb., 111-114
 - artifacts, Feb., 108-110
 - atrioventricular block during, Feb., 113
 - complications of, Feb., 105-123
 - complications of, frequency of, Feb., 106-107
 - complications of, at insertion sites, Feb., 107-108
 - embolic fragments, Feb., 110-111
 - errors, Feb., 108-110
 - indications for, Feb., 100-101
 - intracardiac lesions due to, Feb., 114-116, 117, 118
 - lack of correlation between PAWP and left ventricular end diastolic volume during, Feb., 123-124
 - passage of flow-directed balloon catheter, strip chart pressure recording of, Feb., 99
 - perforation of pulmonary artery due to, Feb., 116-120
 - pneumonectomy and, Feb., 123
 - removal, ventricular tachycardia during, Feb., 114
 - site selection, Feb., 102

- Catheterization (cont.)**
- tachycardia during, sinus, *Feb.*, 113
 - technique, *Feb.*, 102-105
 - thrombotic vegetations on tricuspid valve and endocardium due to, *Feb.*, 116
 - thrombus formation due to, *Feb.*, 120-123
 - tricuspid valve erosion due to, *Feb.*, 115
 - radial artery, complications of, *Feb.*, 81-90
 - of splenorenal shunt, distal, in variceal bleeding, *Mar.*, 167
 - subclavian vein, complications of, *Feb.*, 94-97
- Cattell's pancreaticoduodenal resection technique**, *May*, 332
- Caustic strictures: and esophageal carcinoma**, *July*, 484
- Celiac disease: and esophageal carcinoma**, *July*, 484-485
- Cell(s)**
- antigen-presenting, and prostaglandins, *Nov.*, 736
 - giant (*see* Giant cell)
 - mediated immune response, mechanism of suppression by prostaglandins, *Nov.*, 735-739
 - suppressor, transplantation and prostaglandins, *Nov.*, 739
 - tumor (*see* Tumor, cell)
- Cellular**
- changes in blood after splenectomy, *Dec.*, 778
 - immune interactions, and post-transplant lymphoproliferative disorders, *June*, 438-443
- Central venous catheterization** (*see* Catheterization, central venous)
- Chemotherapy**: for carcinoma of esophagus and cardia, *Aug.*, 592-595
- Child's classification**: of variceal bleeding, *Mar.*, 161-162
- Children**
- fibromatosis in, *Apr.*, 243-244
 - fibrosarcoma in, *Apr.*, 244
 - posttransplant lymphoproliferative disorders in, case presentations, *June*, 417-423, 425-433
- Choledochojejunostomy**, *May*, 352
- Circulatory shock: pharmacologic modulation by prostaglandins**, *Nov.*, 723-725
- Clonal composition of posttransplant lymphoproliferative disorders**, *June*, 400-403
- DNA techniques in, *June*, 450-454
- Clonality of posttransplant lymphoproliferative disorders** (*see* Posttransplant lymphoproliferative disorders, clonality of)
- Coagulation therapy: electrical, for carcinoma of esophagus and cardia**, *Aug.*, 587
- Coccidioidomycosis: after heart transplant**, *Sept.*, 659
- Collagen**
- in desmoid tumors, *Apr.*, 250
 - vascular disorder, fingertip gangrene in, *Jan.*, 20
- Collateral veins: in thoracic outlet syndrome**, *Jan.*, 51
- Colon**
- ascending, desmoid tumor in, *Apr.*, 293
 - as esophageal substitute after esophagogastrectomy, *July*, 519-522
 - interposition, left, for GI reconstruction after esophageal en bloc resection, *Aug.*, 575
 - manifestations of Gardner's stigmata in desmoid tumor patients, *Apr.*, 275-280
- Computed tomography** (*see* Tomography, computed)
- Connective tissue**
- in desmoid tumors, *Apr.*, 251
 - disorders, digital vessels of upper extremity in, *Jan.*, 18, 19
- Corticosteroids: in heart transplantation**, *Sept.*, 648-649
- CT** (*see* Tomography, computed)

- Cyclooxygenase inhibition: effects on Walker carcinosarcoma, *Oct.*, 693
- Cyclosporine: in heart transplantation, *Sept.*, 644–648
- Cytoimmunologic monitoring: in diagnosis of acute cardiac rejection, *Sept.*, 655
- Cytotoxic screen: In heart transplantation, *Sept.*, 622

D

- Death (see Mortality)
- Decompression, selective, for variceal bleeding, *Mar.*, 177–183
- for prevention of recurrent bleeding, *Mar.*, 201–202
- Dermatofibroma: differentiated from desmoid tumor, *Apr.*, 255
- Dermatologic complications: after heart transplant, *Sept.*, 661
- Desjardins' technique: for pancreaticojejunostomy, *May*, 329
- Desmoid syndrome, *Apr.*, 233–320
(See also Desmoid, tumors)
- tissue, sex steroid hormone receptors in, *Apr.*, 285–289
- tumors
- abdominal, clinical appearance of, *Apr.*, 241
 - abdominal, localization of, *Apr.*, 264
 - age distribution, *Apr.*, 264–267, 268–269
 - anatomical distribution of, *Apr.*, 263–264
 - bone anomalies and, inherited, *Apr.*, 281–285
 - around brachial plexus, strategy for removal of, *Apr.*, 295
 - classification of, *Apr.*, 243–249
 - collagen in, *Apr.*, 250
 - in colon, ascending, *Apr.*, 293
 - congenital, *Apr.*, 244
 - connective tissue in, *Apr.*, 251
 - diagnosis, differential, *Apr.*, 249–255
- drugs in, anticancer, *Apr.*, 300–301
- drugs in, nonsteroidal anti-inflammatory, *Apr.*, 301
- etiology of, *Apr.*, 267–275
- extra-abdominal, clinical appearance of, *Apr.*, 241
- extra-abdominal, differential diagnosis of, *Apr.*, 254–255
- extra-abdominal, localization of, *Apr.*, 264
- extra-abdominal, microscopic characteristics of, *Apr.*, 254
- familial, *Apr.*, 244–248
- Gardner's stigmata in, colonic and extracolonic manifestations of, *Apr.*, 275–280
- in gluteal region, angiography of, *Apr.*, 291
- growth behavior of, *Apr.*, 267–275
- growth rate in different age groups, *Apr.*, 266–267
- hip in, *May*, 280
- histologic features of, *Apr.*, 249
- hormonal constitution of female patients and, *Apr.*, 267–274
- in ileal mesentery, *Apr.*, 294
- in ileum, terminal, *Apr.*, 293
- incidence of, *Apr.*, 259–262
- inflammatory focus in periphery of, *Apr.*, 252
- in infraclavicular region, *Apr.*, 297
- inguinal region, right, preoperative strategy for removal of, *Apr.*, 293
- malignant transformation, *Apr.*, 255–259
- mitoses in, *Apr.*, 253
- myxomatously degenerated area in, *Apr.*, 252
- osteoma of jaw in, *Apr.*, 278
- pathology of, *Apr.*, 249
- peroperative strategy, *Apr.*, 291–300
- pregnancy and, *Apr.*, 267–274
- preoperative planning, *Apr.*, 290–300

- Desmoid (cont.)**
- progesterone and, *Apr.*, 288-289
 - radiologic anomalies in, *Apr.*, 277
 - radiologic anomalies in, localization of, *Apr.*, 279
 - radiotherapy for, *Apr.*, 300
 - radiotherapy for, combined with surgery, complications after, *Apr.*, 306
 - radius in, cortical thickening of, *Apr.*, 279
 - recurrence according to age, *Apr.*, 304
 - recurrence according to anatomic region, *Apr.*, 304
 - recurrence according to operational access, *Apr.*, 304
 - recurrence in irradiated area, strategy for removal, *Apr.*, 296
 - recurrence, success rate in sequential attempts to eradicate, *Apr.*, 305
 - recurrence after therapy, *Apr.*, 303
 - in retroperitoneal area, CT of, *Apr.*, 292
 - sarcolemmal giant cells in, *Apr.*, 250
 - in supraclavicular region, *Apr.*, 297
 - surgery for, 289-290
 - surgery for, combined with radiotherapy, complications after, *Apr.*, 306
 - surgery for, complications after, *Apr.*, 306
 - teeth and, *Apr.*, 278
 - trauma and, *Apr.*, 274-275
 - treatment of, *Apr.*, 289-307
 - ultrastructural investigation of, *Apr.*, 249
- Devascularization procedures for variceal bleeding, *Mar.*, 183-184**
- for prevention of recurrent bleeding, *Mar.*, 203
- Diabetes mellitus: as contraindication to heart transplant, *Sept.*, 620**
- Diarrhea: PGE and PGF levels in, *Oct.*, 696**
- Digital**
- artery occlusion due to radial artery catheterization, *Feb.*, 86, 87
 - ischemia, upper extremity drug-induced, *Jan.*, 26
 - primary arterial causes of, *Jan.*, 30
 - systemic diseases causing, *Jan.*, 11
- vessel occlusion, upper extremity**
- in atherosclerosis, *Jan.*, 20
 - in blood dyscrasias, *Jan.*, 25
 - in Buerger's disease, *Jan.*, 25
 - calcium channel blockers for, *Jan.*, 28
- in connective tissue disorders**
- Jan.*, 18, 19
- diseases causing, *Jan.*, 18-29**
- in lupus erythematosus, systemic, *Jan.*, 23-24
- in occupational trauma, *Jan.*, 26-27**
- in polyarteritis nodosa, *Jan.*, 24-25**
- in rheumatoid arthritis, *Jan.*, 23**
- in scleroderma, *Jan.*, 18-20**
- sympathectomy for, *Jan.*, 28-29**
- therapy for, *Jan.*, 27-29**
- therapy for, medical, *Jan.*, 27-28**
- therapy for, operative, *Jan.*, 28-29**
- in ulnar artery thrombosis, *Jan.*, 27**
- in vasculitis (see Vasculitis, upper extremity digital vessels in)**
- Di-M-PGE₂: and melanoma growth in vivo, *Oct.*, 697-700**
- Dizziness: orthostatic, and heart transplant, *Sept.*, 661**
- DNA techniques: in posttransplant lymphoproliferative disorders, *June*, 447-448, 450-454**
- Doppler flow detector, *Jan.*, 12**

- Drug(s)**
- anticancer, in desmoid tumors, *Apr.*, 300-301
 - ischemia due to, upper extremity, *Jan.*, 26
 - nonsteroidal anti-inflammatory, in desmoid tumors, *Apr.*, 301
 - therapy for variceal bleeding, *Mar.*, 168-169
 - for prevention of recurrent bleeding, *Mar.*, 194-195
- Duodenum**
- (*See also* Pancreaticoduodenal resection)
 - site of severance in pylorus-preserving procedure, *May*, 344
- Dyscrasias: blood, digital vessels of upper extremity in, *Jan.*, 25**
- Dysphagia in esophageal carcinoma, *July*, 489-490**
- diagnosis of
 - endoscopic, *July*, 490
 - roentgenographic, *July*, 489-490
 - functional grades of, *July*, 503
- E**
- Edema: due to radial artery catheterization, *Feb.*, 89**
- Eicosanoids**
- actions of, *Oct.*, 681-682
 - degradation of, *Oct.*, 680
 - discussion of term, *Oct.*, 679
 - synthesis of, *Oct.*, 680
 - tumor cells in vitro and, *Oct.*, 683-689
 - tumors in vivo and, *Oct.*, 694-700
- Electrical coagulation therapy: for carcinoma of esophagus and cardia, *Aug.*, 587**
- Electrocardiogram frequency analysis: surface, in diagnosis of acute cardiac rejection, *Sept.*, 656**
- Electrophysiology: of transplanted heart, *Sept.*, 635-636**
- Embolic**
- fragments from pulmonary artery catheterization, *Feb.*, 110-111
 - occlusion of axillary artery, *Jan.*, 40-41
- Embolism: after radial artery catheterization, *Feb.*, 86**
- Endocardium: thrombotic vegetation due to pulmonary artery catheterization, *Feb.*, 116**
- Endomyocardial biopsy: in cardiac rejection, *Sept.*, 651-654**
- Endoscopy**
- in dysphagia in esophageal carcinoma, *July*, 490
 - landmarks of esophagus, *July*, 493
 - sclerotherapy via (see Sclerotherapy, endoscopic variceal) in variceal bleeding, *Mar.*, 162
 - acute, *Mar.*, 191
- Equipment: invasive monitoring mechanical, and infection, *Feb.*, 129-130**
- Epigastrium: posttransplant lymphoproliferative disorder in, *June*, 429, 430**
- Epstein-Barr virus**
- associated posttransplant lymphoproliferative disorders, *June*, 385-389
 - biology, *June*, 376-379
 - infection, *June*, 376-379
 - neoplasia and, *June*, 376-409
- Esophagogastrectomy for carcinoma of esophagus and cardia**
- en bloc, outline of boundaries for abdominal and thoracic portions of, *July*, 517
 - stomach vs. colon as esophageal substitute after, *July*, 519-522
 - transhiatal, *Aug.*, 566-570
 - operative technique, *Aug.*, 566-569
 - results of, *Aug.*, 569-570
 - vs. transthoracic, *July*, 512-514
 - transthoracic, *Aug.*, 560-566
 - operative technique, *Aug.*, 560-565
- reconstruction of gastrointestinal continuity after, *Aug.*, 563**
- results of, *Aug.*, 565-566**

Esophagogastrectomy for carcinoma of esophagus and cardia (*cont.*)

vs. transhiatal, *July*, 512-514

Esophagolaryngectomy: completed, *Aug.*, 558

Esophagus

adenocarcinoma, incidence and etiology of, *July*, 485-487

axis abnormalities, *July*, 495

cancer (see Carcinoma, esophagus and cardia)

carcinoma (see Carcinoma, esophagus and cardia)

endoscopic landmarks of, *July*, 493

lymphatic drainage of, *July*, 498

substitute after esophagogastrectomy, stomach vs. colon for, *July*, 519-522

varices (see Variceal bleeding)

Extremities, upper

digital ischemia of (see Digital ischemia, upper extremity)

digital vessels of (see Digital, vessel occlusion, upper extremity)

hypercoagulable states (see Hypercoagulable states)

vaso-occlusive disorders of (see Vaso-occlusive disorders of upper extremity)

veno-occlusive disorders of, *Jan.*, 44-60

iatrogenic, *Jan.*, 47-48

F

Fatty acids: essential, prostaglandins, and transplantation, *Nov.*, 739-740

Feeding jejunostomy (see Jejunostomy, feeding)

Femoral artery catheterization: complications of, *Feb.*, 90-91

FEV₁: and surgery of esophageal carcinoma, *Aug.*, 543

Fibrinolytic therapy (see Paget-Schroetter syndrome, fibrinolytic therapy for)

Fibromatosis, *Apr.*, 243

classification of, *Apr.*, 310-313

juvenile, *Apr.*, 243-244

Fibrosarcoma

differentiated from extra-abdominal desmoid tumor, *Apr.*, 254

infantile/juvenile, *Apr.*, 244

low-grade, microscopic characteristics of, *Apr.*, 254

Finger gangrene: due to radial artery catheterization, *Feb.*, 89

Fingertip

gangrene in collagen vascular disorder, *Jan.*, 20

infarcts in systemic vasculitis, *Jan.*, 24

FK506: in transplantation, *June*, 389

G

Gangrene

finger, due to radial artery catheterization, *Feb.*, 89

fingertip, in collagen vascular disorder, *Jan.*, 20

Gardner's syndrome, *Apr.*, 248-249

in desmoid tumor patients, colonic and extracolonic manifestations of, *Apr.*, 275-280

Gastric

artery, left, nodal metastases from esophageal carcinoma along, *Aug.*, 561

vessels, short, division for splenectomy, *Dec.*, 815

Gastrocolic omentum: division for anterior approach to splenic vessels, *Dec.*, 817

Gastroduodenal arteries: in pancreaticoduodenal resection, *May*, 343

Gastroesophageal varices (see Variceal bleeding)

Gastrointestinal

(See also Stomach)

continuity, reconstruction after transthoracic esophagectomy, *Aug.*, 563

- tract
 anastomoses after pancreaticoduodenal resection, May, 353
 in Kaposi's sarcoma in renal transplant recipient, June, 435
 reconstruction after esophageal en bloc resection, Aug., 575
- Gene rearrangements (see Post-transplant lymphoproliferative disorders, gene rearrangements in)
- Giant cell(s)
 arteritis, axillary and subclavian arteries in, Jan., 39
 sarcolemmal, in desmoid tumor, Apr., 250
- Globulin
 antilymphocyte, Minnesota, in transplantation, June, 389
 antithymocyte, rabbit, in heart transplantation, Sept., 650
- Gluteal area: desmoid tumor in, angiography of, Apr., 291
- H**
- Head cancer: and esophageal carcinoma, July, 485
- Heart
 catheterization, brachial artery thrombus after, Jan., 44
 disease, etiologies leading to transplantation, Sept., 616
 intracardiac lesions due to pulmonary artery catheterization, Feb., 114-116, 117, 118
 transplantation (see Transplantation, heart)
 xenografting, Sept., 664
- Hemangioendothelioma: differentiated from desmoid tumor, Apr., 255
- Hemangioma: differentiated from desmoid tumor, Apr., 255
- Hematologic evaluation: of variceal bleeding, Mar., 160-161
- Hemodynamic
 effect of endogenous prostaglandins in sepsis and shock, Nov., 722-723
 measurements in variceal bleeding, Mar., 165-167
 monitoring (see Monitoring, invasive)
- Hemodynamics: of transplanted heart, Sept., 635
- Hemostasis: for spleen preservation, Dec., 796-801
- Heparin: in Paget-Schroetter syndrome, Jan., 52
- Hepatic
 (See also Liver)
 arteries
 at gastroduodenal origin, configuration of, May, 343
 in pancreateoduodenectomy, May, 342, 343
- Hepatocyte function: quantitative, in variceal bleeding, Mar., 167-168
- H-graft: portacaval, Mar., 175-176
- Hip: in desmoid tumor patient, May, 280
- Hormone
 constitution of female patients, and desmoid tumors, Apr., 267-274
 sex steroid hormone receptors in desmoid tissue, Apr., 285-289
- Humoral induction: of hypercalcemia, and prostaglandins, Oct., 691-692
- Hypercalcemia syndromes: and prostaglandins, Oct., 690-694
- Hypercoagulable states, upper extremity, Jan., 45-47
 primary, Jan., 46
 secondary, Jan., 45
- Hypersensitivity vasculitis, upper extremity digital vessels in, Jan., 23
 therapy, Jan., 23
- Hypertension (see portal hypertension)

- Iatrogenic**
 immunodeficiency state of organ transplant recipient, *June*, 386-389
- splenic injuries, *Dec.*, 763-766
 veno-occlusive disorders of upper extremity, *Jan.*, 47-48
- ICU**
 monitoring in (see Monitoring, invasive)
 patient, physiologic profile analysis of, *Feb.*, 133
- Ileocecal valve:** from liver transplant recipient with posttransplant lymphoproliferative disorder, *June*, 394
- Ileum**
 mesentery, desmoid tumors in, *Apr.*, 294
 terminal
 desmoid tumor in, *Apr.*, 293
 posttransplant lymphoproliferative disorder of, *June*, 428
- Imaging:** magnetic resonance, of cardiac rejection, *Sept.*, 656
- Immune**
 interactions, and posttransplant lymphoproliferative disorders, *June*, 438-454
 response, cell-mediated, prostaglandins suppressing, *Nov.*, 735-739
- system**
 cancer and, historical considerations, *June*, 373-376
 prostaglandin production by macrophages-monocytes in, *Nov.*, 733-734
 prostaglandins and malignancy, *Oct.*, 689-690
- Immunity:** and heart transplantation, *Sept.*, 638-642
- Immunocytochemical techniques:** for determination of clonality of posttransplant lymphoproliferative disorders, *June*, 446-447
- Immunodeficiency state**
 iatrogenic, of organ transplant recipient, *June*, 386-389
 neoplasms in, *June*, 385
- syndrome**
 acquired, lymphoid tumors in, *June*, 384-385
 congenital, lymphoid tumors in, *June*, 382-384
- Immunoglobulin(s)**
 gene rearrangements (see Post-transplant lymphoproliferative disorders, gene rearrangements in, immunoglobulin)
 response to antigens after splenectomy, *Dec.*, 775-777
 after splenectomy, *Dec.*, 775-777
- Immunology:** of cardiac rejection, *Sept.*, 637-638
- Immunosuppressants**
 in heart transplantation, *Sept.*, 644-650
 recognized sites of action in allogeneic response, *June*, 388
- Immunosuppression**
 blood transfusion-induced, and prostaglandins, *Nov.*, 739
 in heart transplantation (see Transplantation, heart, immunosuppression in)
- Immunosuppressive effect:** of prostaglandins, *Nov.*, 735
- Implantation:** spleen, *Dec.*, 801-805
- Indomethacin**
 effect on cell replication, *Oct.*, 685
 melanoma growth and, *in vivo*, *Oct.*, 697-699
- Infantile fibrosarcoma,** *Apr.*, 244
- Infarction**
 fingertip and nail fold, in systemic vasculitis, *Jan.*, 24
 pulmonary, unresolved, as contraindication to heart transplant, *Sept.*, 619-620
- Infections**
 catheter-related, *Feb.*, 126-129
 identification of, *Feb.*, 125-126

complicating invasive monitoring, *Feb.*, 124-130
after heart transplant (*see* Transplantation, heart, infection after)
lymphoproliferative disorders and, posttransplant, *June*, 412
postsplenectomy (*see* Postsplenectomy infections)
InfrACLAVICULAR region: desmoid tumor in, *Apr.*, 297
Inguinal region: right, preoperative strategy for removal of desmoid tumor from, *Apr.*, 293
Injuries (*see* Trauma)
Inotropic support: and heart transplant, *Sept.*, 626
Intensive care unit (*see* ICU)
Interleukin
-1, prostaglandins and transplantation, *Nov.*, 736-738
-2, prostaglandins and transplantation, *Nov.*, 738
Intracardiac lesions: due to pulmonary artery catheterization, *Feb.*, 114-116, 117, 118
Intravascular devices: infection complicating, *Feb.*, 124-130
Intubation: for advanced carcinoma of esophagus and cardia, *Aug.*, 581-582, 583
Irradiation (*see* Radiotherapy)
Ischemia (*see* Digital ischemia)
Isovolumic relaxation time: in diagnosis of acute cardiac rejection, *Sept.*, 654-655

J

Jaw: osteoma in, in desmoid tumor patient, *Apr.*, 278
Jejunostomy
feeding
catheter, method of securing, *Aug.*, 549
portable pump and, *Aug.*, 550
tube, insertion technique, *Aug.*, 548

Witzel, Aug., 547
Jugular vein catheterization: internal, complications of, *Feb.*, 95-97
Juvenile (*see* Children)

K

Kaposi's sarcoma in renal transplant recipient, *June*, 433-436, 437
case report, *June*, 434-435
follow-up GI series, *June*, 437
GI tract in, *June*, 435
skin lesions in, *June*, 434
stomach in, *June*, 436
Kappa light gene rearrangement: in posttransplant lymphoproliferative disorders, *June*, 449
Karyotypic analysis: Of posttransplant lymphoproliferative disorder, *June*, 403-405
Keloid: differentiated from desmoid tumor, *Apr.*, 254, 255
6-Keto-PGF_{1α}: in female breast masses, *Oct.*, 695
Kidney
dysfunction, irreversible, as contraindication to heart transplant, *Sept.*, 619
transplant (*see* Kaposi's sarcoma in renal transplant recipient)
Kocher maneuver, *May*, 339

L

Laceration
pulmonary artery, due to catheterization, *Feb.*, 119
vertebral artery, due to attempted central venous catheterization, *Feb.*, 96
Laser therapy: of advanced carcinoma of esophagus and cardia, *Aug.*, 586-587
Lavage: peritoneal diagnostic, in splenic injuries, *Dec.*, 769-770

- Ligaments**
 peritoneal, lateral, division for
 spleen mobilization, *Dec.*, 818
 splenocolic, division of, *Dec.*, 816
 splenorenal and splenophrenic,
 division for spleen mobiliza-
 tion, *Dec.*, 812
- Lipoma:** differentiated from des-
 moid tumor, *Apr.*, 255
- Lipoxygenase products:** actions of,
Oct., 682
- Liver**
 biopsy in variceal bleeding, *Mar.*,
 162–163
 dysfunction, irreversible, as con-
 traindication to heart trans-
 plant, *Sept.*, 619
 transplant (see Transplantation,
 liver)
- Lung (see Pulmonary)**
- Lupus erythematosus:** systemic,
 digital vessels of upper ex-
 tremity in, *Jan.*, 23–24
- Lymph node**
 involvement in esophageal carci-
 noma
 classification of, *July*, 497–499
 en bloc resection for cure, *July*,
 515
 metastases from esophageal car-
 cinoma, *Aug.*, 561
- Lymphatic drainage:** of esophagus,
July, 498
- Lymphocytes**
 in desmoid tumors, *Apr.*, 252
 identification methodologies in
 posttransplant lymphoprolif-
 erative disorders, *June*,
 443–445
- Lymphoid tumors**
 in immunodeficiency syndromes
 acquired, *June*, 384–385
 congenital, *June*, 382–384
 in posttransplant lymphoprolifer-
 ative disorders
 benign vs. malignant, *June*,
 454–457
 progression of, *June*, 455
- Lymphoma**
 Burkitt's, *June*, 380–381
- after cyclosporine in heart trans-
 plantation, *Sept.*, 648
- Lymphoproliferative disorders (see**
 Posttransplant lymphoprolif-
 erative disorders)
- M**
- Macfarlane, J., *Apr.*, 234
- Macrophages:** in immune system,
 prostaglandin production by,
Nov., 733–734
- Magnetic resonance imaging: of car-
 diac rejection, *Sept.*, 656
- Malformations (see Anomalies)**
- Malignancy (see Cancer)**
- Mandible:** osteoma in, in desmoid
 tumor patients, *Apr.*, 278
- Mediastinitis:** after heart transplant,
Sept., 658–659
- Melanoma growth in vivo: and
 prostaglandins, *Oct.*, 697–700
- Mesenteric arteriography (see Arte-
 riography, mesenteric)**
- Mesentery:** ileal, desmoid tumor in,
Apr., 294
- Mesoatrial shunt:** for Budd-Chiari
 syndrome, *Mar.*, 213
- Mesogastrium:** dorsal, spleen devel-
 opment in, *Dec.*, 760
- Metastases**
 bony, and prostaglandins, *Oct.*,
 693–694
 distant organ, from esophageal
 carcinoma, classification of,
 July, 499
 nodal, from esophageal carci-
 noma, *Aug.*, 561
- Minnesota antilymphocyte globulin:**
 in transplantation, *June*,
 389
- Mitoses:** in desmoid tumor, *Apr.*,
 253
- Monitoring**
 arterial pressure, *Feb.*, 77–92
 site selection, *Feb.*, 81–82
 cytoimmunologic, in diagnosis of
 acute cardiac rejection, *Sept.*,
 655

- evolution of, Feb., 75-77
 invasive, Feb., 75-145
 complications of, Feb., 75-145
 infection complicating, Feb., 124-130
 mechanical equipment, and infection, Feb., 129-130
 role of, Feb., 130-135
 Monoclonal antibody OKT3: in transplantation, June, 387, 389
 Monocytes: in immune system, prostaglandin production by, Nov., 733-734
 Mortality
 (See also Brain death)
 of esophageal carcinoma surgery
 age and, Aug., 544
 effect of preoperative radiotherapy on, Aug., 590
 after heart transplantation, Sept., 616
 Muscle: pectoral, in desmoid tumor patient, Apr., 299
 Myositis: diffuse subacute, differentiated from desmoid tumor, Apr., 255
 Myxomatously degenerated area: of desmoid tumor, Apr., 252
- N**
- Nail fold infarcts: finger, in systemic vasculitis, Jan., 24
 Neck cancer: and esophageal carcinoma, July, 485
 Necrosis: in posttransplant lymphoproliferative disorder, June, 396
 Neoplasia (see Tumors)
 Neurofibroma: differentiated from desmoid tumor, Apr., 255
 Nifedipine: in vasospastic disorders of upper extremity, Jan., 28
 Nutritional support of esophageal carcinoma patients, Aug., 546-549
 portable pump for, Aug., 550
- Occupational trauma: digital vessels of upper extremity in, Jan., 26-27
 Oculopneumoplethysmographic tracing, Jan., 13
 OKT3: in transplantation, June, 387, 389
 Omentum: gastrocolic, division for anterior approach to splenic vessels, Dec., 817
 Oncogenes: in posttransplant lymphoproliferative disorder, June, 405, 456-457
 OPSI (see Postsplenectomy infections, overwhelming)
 Orthostatic dizziness: after heart transplant, Sept., 661
 Osteoma: in jaw in desmoid tumor patients, Apr., 278
- P**
- Paget-Schroetter syndrome, Jan., 48-60
 axillosubclavian vein repair in, transclavicular approach for, Jan., 58-59
 diagnosis of, Jan., 49-51
 epidemiology of, Jan., 48-49
 fibrinolytic therapy for, Jan., 53-56
 complications of, Jan., 54-56
 contraindications to, Jan., 55
 pathophysiology of, Jan., 52
 surgery for, Jan., 56-60
 therapy for, Jan., 52-60
 Pancreas
 avascular area under neck of, May, 345
 successive sectioning illustrating movement of pancreatic duct to center of gland for two-layer anastomosis, May, 348
 Pancreaticoduodenal resection, May, 327-363
 for adenocarcinoma, results of, May, 359
 Brunschwig's technique, May, 332

- Pancreaticoduodenal resection**
(*cont.*)
Cattell's technique, *May*, 332
conduct of operation, *May*, 336-353
development of, *May*, 327-335
exposure, *May*, 336-337
gastrooduodenal artery in, *May*, 343
hepatic arteries in, *May*, 342, 343
intraoperative decisions, *May*, 337-339
Kocher maneuver in, *May*, 339
for pancreatitis, chronic, results of, *May*, 358
patient preparation for, *May*, 335-336
plane I in, *May*, 339
plane II in, *May*, 341
plane III in, *May*, 345
plane IV in, *May*, 346
postoperative management, *May*, 354-355
pylorus-preserving
site of severance of duodenum in, *May*, 344
Traverso and Longmire's technique, *May*, 334
Watson's technique, *May*, 334
recent experience with, *May*, 328
reconstruction, *May*, 347-353
sequence of anastomoses of gastrointestinal tract after completion of, *May*, 353
resection technique, *May*, 339-347
results of, *May*, 355-360
Whipple's technique, *May*, 331
- Pancreaticoduodenectomy** (*see* Pancreaticoduodenal resection)
Pancreaticojejunostomy
(*See also* Pancreaticoduodenal resection)
Desjardins' technique, *May*, 329
dunking, *May*, 351
end-to-side
initial phase of, *May*, 349
posterior half completed, *May*, 350
- Pancreatitis**
chronic, results of pancreatectoduodenectomy for, *May*, 358
after heart transplantation, *Sept.*, 660
- Paraneoplastic syndromes:** and prostaglandins, *Oct.*, 695-697
- Pectoral muscle:** in desmoid tumor patient, *Apr.*, 299
- Peptic ulcer disease:** as contraindication to heart transplant, *Sept.*, 621
- Peritoneal**
lavage, diagnostic, in splenic injuries, *Dec.*, 769-770
ligaments, lateral, division for spleen mobilization, *Dec.*, 818
- Peritoneovenous shunts:** in ascites, *Mar.*, 216
- Pharmacologic modulation:** of circulatory shock by prostaglandins, *Nov.*, 723-725
- Pharmacotherapy** (*see* Drugs)
- Phlebotomy:** arterial, complications of, *Feb.*, 92
- Physical examination:** in diagnosis of cardiac rejection, *Sept.*, 651
- Physiologic profile analysis:** of ICU patient, *Feb.*, 133
- Physiology:** of transplanted heart, *Sept.*, 634-637
- Pitressin** in variceal bleeding, *Mar.*, 168-169
acute, *Mar.*, 191-192
- Plumbing:** arterial catheter, *Feb.*, 80
- Pneumonectomy:** and pulmonary artery catheterization, *Feb.*, 123
- Polyamines:** urinary, in diagnosis of acute cardiac rejection, *Sept.*, 655
- Polyarteritis nodosa:** digital vessels of upper extremity in, *Jan.*, 24-25
- Portacaval**
H-graft, *Mar.*, 175-176
shunt, end-to-side, schematic of, *Nov.*, 173

- Portal**
hypertension, *Mar.*, 155-223
 etiology of, *Mar.*, 158-159
 history of, *Mar.*, 155-156
systemic shunts (*see* Shunts, portal systemic, total)
vein
 anatomy, *Mar.*, 157-158
 anatomy, on arteriogram, mesenteric, *Mar.*, 164
 anatomy, on arteriogram, splenic, *Mar.*, 165
thrombosis, extrahepatic (*see* Variceal bleeding, in portal vein thrombosis, extrahepatic)
visualization after contrast material, *Mar.*, 166
Postsplenectomy infections, Dec., 779-786
early, *Dec.*, 785-786
overwhelming, *Dec.*, 779-785
 antibiotic prophylaxis, *Dec.*, 805-806
 prevention of, *Dec.*, 805-810
vaccination causing, *Dec.*, 808-809
vaccination preventing, *Dec.*, 806-808
vaccines available for, *Dec.*, 809
Posttransplant lymphoproliferative disorders, June, 371-472
bowel, after renal transplant, *June*, 421, 422
case presentations, *June*, 417-433
clinical considerations, *June*, 409-417
clinical presentation, *June*, 410-412
clonal composition of, *June*, 400-403
DNA techniques in, *June*, 450-454
clonality of
 DNA techniques, *June*, 447-448
immunocytochemical techniques, *June*, 446-447
methodologies for, *June*, 446-454
course of, *June*, 412-416
development of, risk factors for, *June*, 389-392
discussion of term, *June*, 372
in epigastrium, *June*, 429, 430
Epstein-Barr virus-associated, *June*, 385-389
gene rearrangement in
 immunoglobulin, heavy chain, *June*, 453
 immunoglobulin, normal, *June*, 448-450
 immunoglobulin, Southern blotting for, *June*, 451
kappa light, *June*, 449
general summary of, *June*, 372-373
of ileum, terminal, *June*, 428
immune interactions and, *June*, 438-454
infections associated with, *June*, 412
karyotypic analysis of, *June*, 403-405
lymphocyte identification methodologies in, *June*, 443-445
lymphoid tumors in (*see* Lymphoid tumors, in posttransplant lymphoproliferative disorders)
macroscopic appearance, *June*, 392-395
microscopic appearance, *June*, 395-400
monomorphic, *June*, 399
necrosis in, *June*, 396
oncogene expression in, *June*, 405, 456-457
pathogenesis of, hypothesis for, *June*, 406-409
pathology of, *June*, 392-400
patient population, *June*, 409
polymorphic, *June*, 396-397
 minimally, *June*, 398
preliminary comments, *June*, 371-372
pulmonary
 chest x-ray in, *June*, 425, 427
 clinical course of, *June*, 424

- Posttransplant lymphoproliferative disorders (cont.)**
 continuing multinodular infiltrates in, *June*, 426
 specimen processing in, *June*, 416-417
 technical considerations related to study of, *June*, 438-457
 therapy, *June*, 412-416
 time of onset, *June*, 409-410
Pregnancy: and desmoid tumors, *Apr.*, 267-274
Progesterone: effect on desmoid tumors, *Apr.*, 288-289
Prolactin: serum, in diagnosis of acute cardiac rejection, *Sept.*, 655-656
Properdin: after splenectomy, *Dec.*, 777
Propranolol in variceal bleeding, *Mar.*, 169
 for prevention of recurrent bleeding, *Mar.*, 195
Prostacyclin
 actions of, *Oct.*, 682
 blockers, *Nov.*, 721
 release during sepsis and shock, *Nov.*, 716-717
 in shock, septic, *Nov.*, 727
Prostaglandin(s), *Oct.*, 679-706; *Nov.*, 715-747
 analogues, *Oct.*, 682-683
 antigen-presenting cells and, *Nov.*, 736
 biologic role of, *Oct.*, 683
 biosynthesis, *Oct.*, 679-681
 rates related to tumor doubling times, *Oct.*, 686
 blockers, *Nov.*, 721
 bone resorption and, *Oct.*, 690-691
 bony metastases and, *Oct.*, 693-694
 classic, release during sepsis and shock, *Nov.*, 715-716
 differentiation of tumor cells and, *Oct.*, 687-689
E
 actions of, *Oct.*, 681-682
 in diarrhea, *Oct.*, 696
- E₁,** effect on cell replication, *Oct.*, 685
F
 compounds, actions of, *Oct.*, 681-682
 in diarrhea, *Oct.*, 696
F_{1α}, 6-keto, in female breast masses, *Oct.*, 695
 formation in sepsis and shock, inhibition of, *Nov.*, 718-722
 humoral induction of hypercalcemia and, *Oct.*, 691-692
 hypercalcemia syndromes and, *Oct.*, 690-694
I₂ (see Prostacyclin)
 immunosuppressive effect of, *Nov.*, 735
 malignancy and, *Oct.*, 683-700
 immune system and, *Oct.*, 689-690
 melanoma growth in vivo and, *Oct.*, 697-700
 metabolism, *Oct.*, 679-681
 nomenclature, *Oct.*, 681
 paraneoplastic syndromes and, *Oct.*, 695-697
 pharmacologic modulation of circulatory shock by, *Nov.*, 723-725
 production
 by macrophages-monocytes in immune system, *Nov.*, 733-734
 by tumor cells, *Oct.*, 683-686
 by tumors, in vivo, *Oct.*, 694-695
 release
 by allograft antigen stimulation, *Nov.*, 733
 during sepsis and shock, *Nov.*, 715-718
 in sepsis, *Nov.*, 715-733
 effects of, *Nov.*, 718-725
 effects of, hemodynamic, *Nov.*, 722-723
 in shock, *Nov.*, 715-733
 effects of, *Nov.*, 718-725
 effects of, hemodynamic, *Nov.*, 722-723
 septic, clinical, *Nov.*, 725-728

- suppression of cell-mediated immune response by, *Nov.*, 735-739
- in transplantation, *Nov.*, 733-747
c-AMP and, *Nov.*, 735-736
blood transfusion-induced immunosuppression and, *Nov.*, 739
- fatty acids and, essential, *Nov.*, 739-740
- immunosuppressive effect of, *Nov.*, 735
- interleukin-1 and, *Nov.*, 736-738
- interleukin-2 and, *Nov.*, 738
- release by allograft antigen stimulation, *Nov.*, 633
- suppressor cells and, *Nov.*, 739
- tumor cell replication and, *Oct.*, 686-687
- tumor growth control and, *in vivo*, *Oct.*, 697-700
- Psychosocial complications: of heart transplant, *Sept.*, 661
- Pulmonary
- artery catheter (*see* Catheter, pulmonary artery)
 - catheterization (*see* Catheterization, pulmonary artery)
 - perforation due to catheter, *Feb.*, 116-120
- wedge pressure during catheterization, and left ventricular end diastolic volume, *Feb.*, 123-124
- wedge pressure tracing of mechanically ventilated patient, *Feb.*, 109, 110
- infarction, unresolved, as contraindication to heart transplant, *Sept.*, 619-620
- lesions, undiagnosed radiographic, as contraindication to heart transplant, *Sept.*, 620
- posttransplant lymphoproliferative disorders (*see* Posttransplant lymphoproliferative disorders, pulmonary)
- vascular resistance as contraindication to heart transplant, *Sept.*, 619
- Pulse-pressure wave tracings: arterial, *Feb.*, 79
- Q**
- Quality of life: and heart transplant, *Sept.*, 617-618
- R**
- Rabbit antithymocyte globulin: in heart transplantation, *Sept.*, 650
- Radial artery catheterization complications of, *Feb.*, 81-90
thrombosis due to, *Feb.*, 85
- Radiography
- chest
 - in diagnosis of cardiac rejection, *Sept.*, 651
 - in posttransplant lymphoproliferative disorder, *June*, 425, 427
- in dysphagia in esophageal carcinoma, *July*, 489-490
- pulmonary lesions on, undiagnosed, as contraindication to heart transplant, *Sept.*, 620
- Radiology
- anomalies in desmoid tumor patients, *Apr.*, 277
 - localization of, *Apr.*, 279
 - in variceal bleeding, *Mar.*, 163-165
- Radionuclide scanning: in splenic injuries, *Dec.*, 771-772
- Radiotherapy
- for carcinoma of esophagus and cardia (*see under* Carcinoma, esophagus and cardia)
 - for desmoid tumors, *Apr.*, 300
 - combined with surgery, complications after, *Apr.*, 306
 - injury causing axillary artery occlusion, *Jan.*, 39-40

- Radius:** cortical thickening, in desmoid tumor patients, *Apr.*, 279
- Raynaud's disease,** *Jan.*, 7-9
- Raynaud's phenomenon,** *Jan.*, 9-10
- Reitamo syndrome,** *Apr.*, 233-320
(*See also Desmoid, tumors*)
- Renal** (*see Kidney*)
- Reserpine:** in vasospastic disorders of upper extremity, *Jan.*, 27-28
- Resuscitation:** in acute variceal bleeding, *Mar.*, 189-191
- Retroperitoneal area:** CT of desmoid tumor in, *Apr.*, 292
- Rhabdomyoma:** benign, differentiated from desmoid tumor, *Apr.*, 255
- Rheumatoid arthritis:** digital vessels of upper extremity in, *Jan.*, 23
- Rib(s)**
- in desmoid tumor patient, *Apr.*, 299
 - first, transaxillary approach to resection, for thoracic outlet compression syndrome, *Jan.*, 60
- Rupture** (*see Spleen, rupture*)
- S**
- Sarcolemmal giant cells:** in desmoid tumor, *Apr.*, 250
- Sarcoma** (*see Kaposi's sarcoma in renal transplant recipient*)
- Scanning:** radionuclide, in splenic injuries, *Dec.*, 771-772
- Schistosomiasis:** variceal bleeding in, *Mar.*, 209
- Scleroderma:** digital vessels of upper extremity in, *Jan.*, 18-20
- Sclerosis, endoscopic** (*see Sclerotherapy, endoscopic variceal*)
- Sclerotherapy, endoscopic variceal**
- Mar.*, 170-172
 - complications of, *Mar.*, 172
 - for prevention of recurrent bleeding, *Mar.*, 196-199
- Sepsis**
- prostacyclin release during, *Nov.*, 716-717
 - prostaglandin(s) in, *Nov.*, 715-733
 - effects of, *Nov.*, 718-725
 - effects of, hemodynamic, *Nov.*, 722-723
 - prostaglandin formation inhibition in, endogenous, *Nov.*, 718-722
 - prostaglandin release during, *Nov.*, 715-718
 - classic, *Nov.*, 715-716
 - thromboxane release during, *Nov.*, 717-718
- Septic shock:** clinical, prostaglandins in, *Nov.*, 725-728
- Sex steroid hormone receptors:** in desmoid tissue, *Apr.*, 285-289
- Shock**
- circulatory, pharmacologic modulation by prostaglandins, *Nov.*, 723-725
 - prostacyclin release during, *Nov.*, 716-717
 - prostaglandin(s) in, *Nov.*, 715-733
 - effects of, *Nov.*, 718-725
 - effects of, hemodynamic, *Nov.*, 722-723
 - prostaglandin formation inhibition in, endogenous, *Nov.*, 718-722
 - prostaglandin release during, *Nov.*, 715-718
 - classic, *Nov.*, 715-716
 - septic, clinical, prostaglandins in, *Nov.*, 725-728
 - thromboxane release during, *Nov.*, 717-718
- Shunts**
- mesoatrial, for Budd-Chiari syndrome, *Mar.*, 213
 - peritoneovenous, in ascites, *Mar.*, 216
 - portacaval, end-to-side, schematic of, *Nov.*, 173
 - portal systemic, total
 - in ascites, *Mar.*, 216
 - side-to-side, examples of, *Mar.*, 174

- in variceal bleeding, *Mar.*, 172-177
in variceal bleeding, for prevention of recurrent bleeding, *Mar.*, 199-201
splenorenal, distal, *Mar.*, 177
arteriogram after, mesenteric, *Mar.*, 182
catheterization, in variceal bleeding, *Mar.*, 167
operative steps in, *Mar.*, 179-181
for prevention of recurrent variceal bleeding, *Mar.*, 201-202
Sinus tachycardia: during pulmonary artery catheterization, *Feb.*, 113
Skin lesions: in Kaposi's sarcoma in renal transplant recipient, *June*, 434
Smokers: esophageal cancer in, *July*, 483
Southern blotting: for immunoglobulin gene rearrangements in posttransplant lymphoproliferative disorders, *June*, 451
Spironolactone: in ascites, *Mar.*, 215-216
Spleen
accessory, *Dec.*, 786-787
anatomy of, *Dec.*, 758-762
appearance of, gross, *Dec.*, 759
angiography (see Arteriography, splenic)
development in dorsal mesogastrium, *Dec.*, 760
elevation, surgical, *Dec.*, 761
function after splenectomy, *Dec.*, 775-779
implantation of, *Dec.*, 801-805
injuries, *Dec.*, 757-832
angiography in, splenic, *Dec.*, 770-771
causes of, *Dec.*, 762-768
diagnosis of, *Dec.*, 768-775
diagnosis of, conventional methods, *Dec.*, 768-769
external trauma causing, *Dec.*, 763
iatrogenic, *Dec.*, 763-766
implantation-transplantation in, *Dec.*, 801-805
management of, nonoperative, *Dec.*, 791-796
operative preservation of spleen for (see Spleen, operative preservation for splenic injuries)
peritoneal lavage in, diagnostic, *Dec.*, 769-770
radionuclide scanning in, *Dec.*, 771-772
tomography in, computed, *Dec.*, 772-774
types of, *Dec.*, 762-768
ultrasound in, diagnostic, *Dec.*, 771
mobilization
by division of lateral peritoneal ligaments, *Dec.*, 818
by division of splenorenal and splenophrenic ligaments, *Dec.*, 812
operative preservation for splenic injuries, *Dec.*, 796-801
clinical experience, *Dec.*, 796-799
experimental evidence for, *Dec.*, 799-801
repair, *Dec.*, 816-818, 819
resection, partial, *Dec.*, 816-818, 819
rupture
delayed, *Dec.*, 766-767
occult, *Dec.*, 767-768
surgical approach through ventricular midline abdominal incision, *Dec.*, 811
transplantation, *Dec.*, 801-805
Splenectomy
cellular changes in blood after, *Dec.*, 788
gastric vessels in, short, division of, *Dec.*, 815
immunoglobulins and response of immunoglobulins to antigens after, *Dec.*, 775-777
infections after (see Postsplenectomy infections)
partial, *Dec.*, 796-801

- Splenectomy (cont.)**
 (See also Spleen, operative preservation for splenic injuries)
 properdin after, Dec., 777
 splenic function after, Dec., 775-779
 technique, Dec., 810-816, 817
 tuftsin after, Dec., 777
- Splenic**
 artery, major branches of, Dec., 762
 vessels
 anterior approach to, by initial division of gastrocolic omentum, Dec., 817
 blunt dissection for exposure in posterior aspect of splenic hilus, Dec., 813
 ligation and division of, Dec., 814
- Splenocolic ligament:** division for splenectomy, Dec., 816
- Splenophrenic ligaments:** division for spleen mobilization, Dec., 812
- Splenorenal**
 ligaments, division for mobilization of spleen, Dec., 812
 shunts (see Shunts, splenorenal, distal)
- Splenorrhaphy, Dec.**, 796-801
 (See also Spleen, operative preservation for splenic injuries)
- Splenosis, Dec.**, 787-791
- Steroid(s)**
 corticosteroids in heart transplantation, Sept., 648-649
 sex steroid hormone receptors in desmoid tissue, Apr., 285-289
- Stomach**
 (See also Gastrointestinal)
 as esophageal substitute after esophagogastrectomy, July, 519-522
 in Kaposi's sarcoma in renal transplant recipient, June, 436
 preparation for pull-up into chest or neck, Aug., 556
- Streptokinase:** in Paget-Schroetter syndrome, Jan., 53-54
- Stricture:** caustic, and esophageal carcinoma, July, 484
- Subclavian artery**
 in arteritis, giant cell, Jan., 39
 in desmoid tumor patient, Apr., 298
 occlusive lesions, Jan., 31-34
 occlusive lesions, surgical correction, Jan., 32-34
 surgical exposure, Jan., 34
 steal, reconstructive procedure for, Jan., 33
- vein**
 catheterization, complications of, Feb., 94-97
 occlusion due to desmoid tumor, Apr., 298
 occlusion in thoracic outlet compression syndrome, Jan., 50
- Suppressor cells:** transplantation and prostaglandins, Nov., 739
- Supraclavicular region:** desmoid tumor in, Apr., 297
- Sympathectomy:** for vasospastic disorders of upper extremity, Jan., 28-29
- Swallowing abilities:** after therapies for cervical esophageal carcinoma, Aug., 553

T

- Tachycardia during pulmonary artery catheterization**
 sinus, Feb., 113
 ventricular, Feb., 114
- Tamponade for variceal bleeding,**
 Mar., 169-170
 acute, Mar., 192
- Teeth:** in desmoid tumor patients, Apr., 278
- Thoracic outlet syndrome, Jan.**, 34-37
- brachial artery thrombus from subclavian lesion in, Jan., 35
- collateral veins in, Jan., 51

- operative correction, Jan., 36-37
rib resection for, first, transaxillary approach to, Jan., 60
subclavian vein occlusion in, Jan., 50
- Thrombolytic therapy (see Paget-Schroetter syndrome, fibrinolytic therapy for)
- Thrombosis
portal vein (see Variceal bleeding, in portal vein thrombosis)
radial artery, due to catheterization, Feb., 85
ulnar artery, digital vessels in, Jan., 27
- Thrombotic vegetation: endocardium and tricuspid valve, due to pulmonary artery catheterization, Feb., 116
- Thromboxane
actions of, Oct., 682
blockers, Nov., 721
in breast masses, female, Oct., 695
release during sepsis and shock, Nov., 717-718
in shock, septic, Nov., 727
- Thrombus
brachial artery
after cardiac catheterization, Jan., 44
from subclavian lesion in thoracic outlet syndrome, Jan., 35
formation due to pulmonary artery catheterization, Feb., 120-123
- Thyroid: in desmoid tumor patient, Apr., 299
- Tomography, computed
of desmoid tumor in retroperitoneal area, Apr., 292
in splenic injuries, Dec., 772-774
- Toxoplasmosis: after heart transplant, Sept., 659
- Transfusion-induced immunosuppression: and prostaglandins, Nov., 739
- Transplantation
antigen stimulation, prostaglandin release by, Nov., 733
- antilymphocyte globulin in, Minnesota, June, 389
FK506 in, June, 389
heart (see below)
kidney (see Kaposi's sarcoma in renal transplant recipient)
liver, for variceal bleeding, Mar., 184-187
methods, Mar., 186, 187, 188
for prevention of recurrent bleeding, Mar., 204
- lymphoproliferative disorders after (see Posttransplant lymphoproliferative disorders)
- OKT3 in, June, 387, 389
- prostaglandins in (see Prostaglandins, in transplantation)
recipients, iatrogenic immunodeficiency state of, June, 386-389
- spleen, Dec., 801-805
- Transplantation, heart, Sept., 613-672
antithymocyte globulin in, rabbit, Sept., 650
appearance of heart at end of transplant procedure, Sept., 632
- arteriosclerosis after, accelerated graft, Sept., 659-660
- azathioprine in, Sept., 649-650
- brain death and, Sept., 625, 628-629
- bridge to transplantation, Sept., 663-664
- coccidioidomycosis after, Sept., 659
- complications after, Sept., 657-661
psychosocial, Sept., 661
- contraindication(s) to, Sept., 618-621
age as, Sept., 618-619
cachexia as, Sept., 620
- diabetes mellitus as, Sept., 620
- hepatic dysfunction as, irreversible, Sept., 619
- inability to comply with medical therapy as, Sept., 620
- malignancy as, Sept., 621

- Transplantation, heart (*cont.*)
other organ transplant as,
Sept., 620
peptic ulcer disease as, *Sept.*,
621
pulmonary infarction as, unre-
solved, *Sept.*, 619-620
pulmonary lesions as, undi-
agnosed radiographic, *Sept.*,
620
pulmonary vascular resistance
as, *Sept.*, 619
renal dysfunction as, irrevers-
ible, *Sept.*, 619
corticosteroids in, *Sept.*, 648-649
cyclosporine in, *Sept.*, 644-648
cytotoxic screen in, *Sept.*, 622
donor, *Sept.*, 622-627
anatomy of donor heart prior
to implantation, *Sept.*, 631
donor care, *Sept.*, 629
donor selection, *Sept.*, 624-627
absence of other factors, *Sept.*,
626-627
age and, *Sept.*, 625
anticipated ischemic time and,
Sept., 627
brain death and, *Sept.*, 625
criteria for, *Sept.*, 625-626
inotropic support and, *Sept.*,
626
electrophysiology after, *Sept.*,
635-636
etiologies of cardiac disease lead-
ing to, *Sept.*, 616
future of, *Sept.*, 663-664
heart metabolism after, *Sept.*,
636-637
heart physiology after, *Sept.*,
634-637
heart rate after, *Sept.*, 634-635
hemodynamics after, *Sept.*, 635
heterotopic, technique and cri-
tique of, *Sept.*, 633
history, *Sept.*, 613-616
immunity and, *Sept.*, 638-642
immunosuppression in, *Sept.*,
642-644
quadruple therapy, *Sept.*, 644,
645
quadruple therapy, survival af-
ter, *Sept.*, 638
immunosuppressive agents in,
Sept., 644-650
infection after, *Sept.*, 657-659
prevention, diagnosis and treat-
ment of, *Sept.*, 657-658
probability of freedom from, in
quadruple therapy patients,
Sept., 639
matching requirements with do-
nor, *Sept.*, 621-622
ABO blood group compatibility,
Sept., 621-622
size, *Sept.*, 621
mediastinitis after, *Sept.*, 658-659
modern era of, time line for,
Sept., 614
mortality after, *Sept.*, 616
number by year since 1973, *Sept.*,
615
orthotopic, *Sept.*, 629-631
procedure, *Sept.*, 629-631
recipient selection, *Sept.*,
616-621
considerations after, *Sept.*,
621-622
functional ability and, *Sept.*,
616-617
prognosis and, *Sept.*, 616-617
quality of life and, *Sept.*,
617-618
rejection
acute, and immunity, *Sept.*,
640-642
diagnosis (*see below*)
hyperacute, and immunity,
Sept., 638-640
immunology of, *Sept.*, 637-638
probability of freedom from, in
quadruple therapy patients,
Sept., 639
rejection, diagnosis, *Sept.*,
650-656
clinical approach, *Sept.*, 651-654
cytoimmunologic monitoring
in, *Sept.*, 655
electrocardiogram in, surface,
frequency analysis of, *Sept.*,
656

- endomyocardial biopsy in, *Sept.*, 651–654
 history in, *Sept.*, 651
 isovolumic relaxation time in, *Sept.*, 654–655
 noninvasive, *Sept.*, 654–656
 physical examination in, *Sept.*, 651
 prolactin in, serum, *Sept.*, 655–656
 roentgenogram in, chest, *Sept.*, 651
 urinary polyamines in, *Sept.*, 655
 survival after, *Sept.*, 662–663
 sympathetic control mechanisms after, *Sept.*, 636–637
 technical safeguards in, *Sept.*, 631–633
 toxoplasmosis after, *Sept.*, 659
 xenotransplantation, *Sept.*, 664
- Trauma
 axillary artery, causing occlusion, *Jan.*, 40
 desmoid tumors and, *Apr.*, 274–275
 occupational, digital vessels of upper extremity in, *Jan.*, 26–27
 spleen (see Spleen, injuries)
- Traverso and Longmire's pancreatoduodenectomy, *May*, 334
- Tricuspid valve
 erosion due to Swan-Ganz catheter, *Feb.*, 115
 thrombotic vegetation due to pulmonary artery catheterization, *Feb.*, 116
- Tuftsin: after splenectomy, *Dec.*, 777
- Tumor(s)
 cell(s)
 differentiation, and prostaglandins, *Oct.*, 687–689
 in vitro, and eicosanoids, *Oct.*, 683–689
 prostaglandin production by, *Oct.*, 683–686
 replication, effects of prostaglandins on, *Oct.*, 686–687
 desmoid (see Desmoid, tumors)
- doubling times related to prostaglandin biosynthesis rates, *Oct.*, 686
 Epstein-Barr virus and, *June*, 376–409
 growth control in vivo, and prostaglandins, *Oct.*, 697–700
 in immunodeficiency states, *June*, 385
in vivo
 eicosanoids and, *Oct.*, 694–700
 prostaglandin production by, *Oct.*, 694–695
 lymphoid (see Lymphoid tumors)
 TXA₂ (see Thromboxane)
 Tylosis: and esophageal carcinoma, *July*, 484
- U**
- Ulcer disease: peptic, as contraindication to heart transplant, *Sept.*, 621
- Ulnar artery thrombosis: digital vessels in, *Jan.*, 27
- Ultrasound: diagnostic, in splenic injuries, *Dec.*, 771
- Ultrastructural investigation: of desmoid tumors, *Apr.*, 249
- Urinary polyamines: in diagnosis of acute cardiac rejection, *Sept.*, 655
- Urokinase: in Paget-Schroetter syndrome, *Jan.*, 53, 54
- V**
- Vaccination
 causing overwhelming postsplenectomy infection, *Dec.*, 808–809
 preventing overwhelming postsplenectomy infections, *Dec.*, 806–808
- Vaccines: for overwhelming postsplenectomy infections, *Dec.*, 809
- Valve (see Tricuspid valve)

- Variceal bleeding
acute
endoscopy in, Mar., 191
management of, Mar., 189-192
pitressin in, Mar., 191-192
resuscitation in, Mar., 189-191
tamponade in, Mar., 192
- biopsy in, liver, Mar., 162-163
- Child's classification, Mar., 161-162
- decompression for, selective, Mar., 177-183
- devascularization procedures for, Mar., 183-184
- diagnosis of, Mar., 159-168
biochemical, Mar., 161
clinical, Mar., 160
endoscopic, Mar., 162
hematologic, Mar., 160-161
- first bleed, prophylactic therapy for prevention of, Mar., 204-206
- hemodynamic measurements in, Mar., 165-167
- hepatocyte function in, quantitative, Mar., 167-168
- liver transplantation for, Mar., 184-187
methods, Mar., 186, 187, 188
management of, Mar., 187-209
operation for, emergency, Mar., 192
- pharmacotherapy for, Mar., 168-169
- in portal vein thrombosis, extrahepatic, Mar., 206-209
angiogram in, mesenteric, Mar., 207
- management schema, Mar., 208
- radiology in, Mar., 163-165
- recurrent, prevention of, Mar., 193-204
decompression for, selective, Mar., 201-202
devascularization procedures for, Mar., 203
- liver transplantation for, Mar., 204
- pharmacotherapy for, Mar., 194-195
- propranolol for, Mar., 195
- schema for, Mar., 205
- shunts for, total portal systemic, Mar., 199-201
- in schistosomiasis, Mar., 209
- sclerotherapy for (see Sclerotherapy, endoscopic variceal)
- shunts for
portal systemic, total, Mar., 172-177
- splenorenal (see Shunts, splenorenal, distal)
- in specialized conditions, Mar., 206-209
- tamponade for, Mar., 169-170
- treatment of, Mar., 168-187
- Vasculitis, upper extremity digital vessels in, Jan., 20-23
- diagnosis, Jan., 22
- hypersensitivity, Jan., 23
therapy, Jan., 23
- spectrum of, Jan., 21
- systemic, fingertip and nail fold infarcts in, Jan., 24
- Vaso-occlusive disorders of upper extremity, Jan., 7-67
- Digital (see Digital vessel occlusion, upper extremity)
- small artery, Jan., 7-18
algorithm in, clinical, Jan., 15
- angiography in (see Arteriography, in small artery occlusive disorders of upper extremity)
- epidemiology of, Jan., 17-18
- noninvasive tests in, Jan., 10-15
- Vegetations: thrombotic, on tricuspid valve and endocardium due to pulmonary artery catheterization, Feb., 116
- Vein
axillosubclavian, repair in Paget-Schroetter syndrome, transclavicular approach for, Jan., 58-59
- central venous catheterization (see Catheterization, central venous)
- collateral, in thoracic outlet syndrome, Jan., 51

- jugular, internal, catheterization,**
complications of, *Feb.*, 95-97
- occlusive disorders of upper extremity, Jan., 44-60**
- iatrogenic, Jan., 47-48**
- portal (see Portal, vein)**
- subclavian (see Subclavian, vein)**
- Ventricle**
- left, end diastolic volume, and PAWP during pulmonary artery catheterization, *Feb.*, 123-124
- tachycardia during pulmonary artery catheter removal, *Feb.*, 114
- Vertebral artery laceration: due to attempted central venous catheterization, Feb., 96**
- Vessels**
- (See also Vaso-occlusive disorders of upper extremity)
- brachiocephalic, reconstruction techniques using, *Jan.*, 32
- digital (see Digital, vessel occlusion, upper extremity)
- gastric, short, division for splenectomy, *Dec.*, 815
- great, after cardiectomy, *Sept.*, 630
- intravascular devices, infection complicating, *Feb.*, 124-130
- pulmonary vascular resistance as contraindication to heart transplant, *Sept.*, 619
- splenic (see Splenic, vessels)
- Virus (see Epstein-Barr virus)**
- W**
- Walker carcinosarcoma: effects of cyclooxygenase inhibition on, *Oct.*, 693
- Watson's pancreatoduodenectomy, May, 334**
- Whipple's pancreatoduodenectomy, May, 331**
- Witzel jejunostomy, Aug. 547**
- X**
- Xenografting: cardiac, Sept., 664**